Drugs / SCB01A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01159522 | Apr 2011 → Jul 2017 | cancer | SynCore Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03020823 | Apr 2017 → Nov 2018 | head and neck neoplasm | SynCore Biotechnology Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT02488629 | Sep 2015 → Dec 2017 | head and neck squamous cell carcinoma | SynCore Biotechnology Co., Ltd. | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01151930 | — | cancer | SynCore Biotechnology Co., Ltd. | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCB01A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01151930 ↗ |
| Action | Inhibit | “SCB01A, a novel microtubule inhibitor” PMID 33245172 ↗ Dec 2020 |
| Route | Intravenous | “administered intravenous SCB01A infusions” PMID 33245172 ↗ Dec 2020 |